Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series
We present pharmacokinetic data on long-acting cabotegravir/rilpivirine (LA CAB/RPV) from two patients during their second and third trimesters. Monthly LA CAB/RPV dosing maintained concentrations above the proposed efficacy thresholds while bimonthly dosing resulted in subtherapeutic RPV concentrations. This highlights the potential of monthly LA CAB/RPV dosing in pregnancy.
Authors
- Anthony T. Podany (ORCID: https://orcid.org/0000-0002-8371-0379)
- Kimberly K. Scarsi (ORCID: https://orcid.org/0000-0001-9406-693X)
- Joshua P Havens (ORCID: https://orcid.org/0000-0001-9894-615X)
- Lee C. Winchester (ORCID: https://orcid.org/0000-0002-6118-024X)
- Timothy Mykris (ORCID: https://orcid.org/0000-0002-0959-6563)
- Maureen Kubat
- Jennifer M Davis (ORCID: https://orcid.org/0000-0002-4971-1490)
- Sara Hurtado Bares (ORCID: https://orcid.org/0000-0002-2130-2505)
- Christine Tran
- Shawnalyn W Sunagawa (ORCID: https://orcid.org/0009-0005-3068-3732)
- Carly Cloud Floyd (ORCID: https://orcid.org/0000-0001-9316-5610)
- Jennifer O’Neill (ORCID: https://orcid.org/0000-0002-1430-0851)
- Jeremy Snyder
Institutions
- Nebraska Medical Center (US)
- University of New Mexico (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1093/ofid/ofaf649
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40